Long-term follow-up of bezafibrate treatment in patients with the myopathic form of carnitine palmitoyltransferase 2 deficiency
- PMID: 20505667
- DOI: 10.1038/clpt.2010.55
Long-term follow-up of bezafibrate treatment in patients with the myopathic form of carnitine palmitoyltransferase 2 deficiency
Abstract
Carnitine palmitoyltransferase 2 (CPT2) deficiency is a rare mitochondrial fatty acid oxidation (FAO) disorder characterized by myalgia, exercise intolerance, and rhabdomyolysis. We evaluate the efficacy of bezafibrate (BZ), a hypolipidemic drug, as a treatment for this form of CPT2 deficiency. A pilot trial was conducted with BZ in six patients for 6 months. There was a follow-up period of 3 years. The oxidation rates of the long-chain fatty acid derivative palmitoyl-CoA, measured in the mitochondria of the patients' muscles, were markedly lower than normal before treatment and increased significantly (+39 to +206%; P = 0.028) in all patients after BZ treatment. The evaluation of the therapeutic effects by the patients themselves (using the Short Form Health Survey (SF-36)), as well as by the physicians, indicated an improvement in the condition of the patients; there was an increase in physical activity and a decline in muscular pain. The results suggest that BZ has a therapeutic effect in the muscular form of CPT2 deficiency.
Similar articles
-
Bezafibrate increases very-long-chain acyl-CoA dehydrogenase protein and mRNA expression in deficient fibroblasts and is a potential therapy for fatty acid oxidation disorders.Hum Mol Genet. 2005 Sep 15;14(18):2695-703. doi: 10.1093/hmg/ddi303. Epub 2005 Aug 22. Hum Mol Genet. 2005. PMID: 16115821
-
Diagnostic assessment and long-term follow-up of 13 patients with Very Long-Chain Acyl-Coenzyme A dehydrogenase (VLCAD) deficiency.Neuromuscul Disord. 2009 May;19(5):324-9. doi: 10.1016/j.nmd.2009.02.007. Epub 2009 Mar 26. Neuromuscul Disord. 2009. PMID: 19327992
-
Fuel utilization in subjects with carnitine palmitoyltransferase 2 gene mutations.Ann Neurol. 2005 Jan;57(1):60-6. doi: 10.1002/ana.20320. Ann Neurol. 2005. PMID: 15622536
-
New genetic defects in mitochondrial fatty acid oxidation and carnitine deficiency.Adv Pediatr. 1987;34:59-88. Adv Pediatr. 1987. PMID: 3318304 Review.
-
Carnitine palmitoyltransferase deficiencies.Mol Genet Metab. 1999 Dec;68(4):424-40. doi: 10.1006/mgme.1999.2938. Mol Genet Metab. 1999. PMID: 10607472 Review.
Cited by
-
Targeting lipid metabolism as a new therapeutic strategy for inherited cardiomyopathies.Front Cardiovasc Med. 2023 Jan 19;10:1114459. doi: 10.3389/fcvm.2023.1114459. eCollection 2023. Front Cardiovasc Med. 2023. PMID: 36760574 Free PMC article. Review.
-
Clinical and biochemical footprints of inherited metabolic disorders: X. Metabolic myopathies.Mol Genet Metab. 2022 Sep-Oct;137(1-2):213-222. doi: 10.1016/j.ymgme.2022.09.004. Epub 2022 Sep 18. Mol Genet Metab. 2022. PMID: 36155185 Free PMC article. Review.
-
Disturbance of Mitochondrial Dynamics, Endoplasmic Reticulum-Mitochondria Crosstalk, Redox Homeostasis, and Inflammatory Response in the Brain of Glutaryl-CoA Dehydrogenase-Deficient Mice: Neuroprotective Effects of Bezafibrate.Mol Neurobiol. 2022 Aug;59(8):4839-4853. doi: 10.1007/s12035-022-02887-3. Epub 2022 May 31. Mol Neurobiol. 2022. PMID: 35639256
-
HRAS germline mutations impair LKB1/AMPK signaling and mitochondrial homeostasis in Costello syndrome models.J Clin Invest. 2022 Apr 15;132(8):e131053. doi: 10.1172/JCI131053. J Clin Invest. 2022. PMID: 35230976 Free PMC article.
-
Exercise, Nutrition, and Supplements in the Muscle Carnitine Palmitoyl-Transferase II Deficiency: New Theoretical Bases for Potential Applications.Front Physiol. 2021 Aug 2;12:704290. doi: 10.3389/fphys.2021.704290. eCollection 2021. Front Physiol. 2021. PMID: 34408664 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical